International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors-Reference-Cited by-同舟云学术

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors

Published:2019-02-06 Issue:6 Volume:42 Page:1147-1154
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Danne Thomas¹^ORCID,Garg Satish²,Peters Anne L.³,Buse John B.⁴^ORCID,Mathieu Chantal⁵^ORCID,Pettus Jeremy H.⁶^ORCID,Alexander Charles M.⁷,Battelino Tadej⁸^ORCID,Ampudia-Blasco F. Javier⁹,Bode Bruce W.¹⁰^ORCID,Cariou Bertrand¹¹^ORCID,Close Kelly L.¹²,Dandona Paresh¹³^ORCID,Dutta Sanjoy¹⁴,Ferrannini Ele¹⁵^ORCID,Fourlanos Spiros¹⁶^ORCID,Grunberger George¹⁷,Heller Simon R.¹⁸^ORCID,Henry Robert R.⁶^ORCID,Kurian Martin J.¹⁹,Kushner Jake A.²⁰^ORCID,Oron Tal²¹²²,Parkin Christopher G.²³^ORCID,Pieber Thomas R.²⁴,Rodbard Helena W.²⁵^ORCID,Schatz Desmond²⁶,Skyler Jay S.²⁷,Tamborlane William V.²⁸,Yokote Koutaro²⁹^ORCID,Phillip Moshe²¹²²^ORCID

Affiliation:

1. Diabetes Centre for Children and Adolescents, Kinder- und Jugendkrankenhaus Auf der Bult, Hannover, Germany

2. University of Colorado Denver and Barbara Davis Center for Diabetes, Aurora, CO

3. Keck School of Medicine of the University of Southern California, Los Angeles, CA

4. University of North Carolina School of Medicine, Chapel Hill, NC

5. Department of Endocrinology, UZ Gasthuisberg, KU Leuven, Leuven, Belgium

6. Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, San Diego, CA

7. Alexander Associates LLC, Gwynedd Valley, PA

8. Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, University Children’s Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Slovenia

9. Clinic University Hospital of Valencia, Valencia, Spain

10. Atlanta Diabetes Associates, Atlanta, GA

11. Clinique d'endocrinologie, L'institut du thorax, CHU Nantes, CIC 1413 INSERM, Nantes, France

12. The diaTribe Foundation, San Francisco, CA

13. Division of Endocrinology, Diabetes and Metabolism, University at Buffalo, The State University of New York, Buffalo, NY

14. JDRF International, New York, NY

15. National Research Council (CNR) Institute of Clinical Physiology, Pisa, Italy

16. Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Melbourne, Australia

17. Grunberger Diabetes Institute, Bloomfield Hills, MI

18. Academic Unit of Diabetes, Endocrinology & Metabolism, University of Sheffield, Sheffield, U.K.

19. Close Concerns, San Francisco, CA

20. McNair Interests, Houston, TX

21. Jesse Z and Sara Lea Shafer Institute of Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel

22. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

23. CGParkin Communications, Inc., Boulder City, NV

24. Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

25. Endocrine and Metabolic Consultants, Rockville, MD

26. Division of Endocrinology, Department of Pediatrics, University of Florida, Gainesville, FL

27. Division of Endocrinology, Diabetes and Metabolism, Miller School of Medicine, University of Miami, Miami, FL

28. Department of Pediatrics, Yale School of Medicine, New Haven, CT

29. Department of Diabetes, Metabolism and Endocrinology, Chiba University Graduate School of Medicine, Chiba, Japan

Abstract

Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolute risk of diabetic ketoacidosis (DKA). Some cases presented with near-normal blood glucose levels or mild hyperglycemia, complicating the recognition/diagnosis of DKA and potentially delaying treatment. Several SGLT inhibitors are currently under review by the U.S. Food and Drug Administration and European regulatory agencies as adjuncts to insulin therapy in people with type 1 diabetes. Strategies must be developed and disseminated to the medical community to mitigate the associated DKA risk. This Consensus Report reviews current data regarding SGLT inhibitor use and provides recommendations to enhance the safety of SGLT inhibitors in people with type 1 diabetes.

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/42/6/1147/552929/dc182316.pdf

Reference45 articles.

1. Hypoglycemia: still the limiting factor in the glycemic management of diabetes;Cryer;Endocr Pract,2008

2. Insulin omission in women with IDDM;Polonsky;Diabetes Care,1994

3. Assessment of diabetes-related distress;Polonsky;Diabetes Care,1995

4. Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study;Peyrot;Curr Med Res Opin,2009

5. U.S. Food and Drug Administration. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [Internet], 15 May 2015. Available from https://www.fda.gov/downloads/drugs/drugSafety/ucm446954.pdf. Accessed 25 May 2018

Cited by 256 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Treatment with SGLT-2 Inhibitors is Associated with ICU Admission and Disease Severity in Patients with Diabetic Ketoacidosis: A Propensity Score–Matched Cohort Study;2024-09-09

2. Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin;Diabetes Technology & Therapeutics;2024-09-01

3. SGLT‐2 inhibitors and high‐dose acarbose as potential high‐risk combinations for ketosis and ketoacidosis in Asian patients with T2DM: A case series;Clinical Case Reports;2024-09

4. Examining capillary ketone testing in hospitalised patients: indications and outcomes;Internal Medicine Journal;2024-08-28

5. Elevated urinary albumin predicts increased time in range after initiation of SGLT2 inhibitors in individuals with type 1 diabetes on sensor-augmented pump therapy;Diabetology International;2024-08-06